JUNS (Jupiter Neurosciences) Total Payout Yield %: 0.00 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.17
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences Total Payout Yield %?

Jupiter Neurosciences JUNS -2.52% 4 Total Payout Yield % is 0.00 as of Jul. 17, 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Jupiter Neurosciences's current Total Payout Yield % is 0.00%.

Jupiter Neurosciences Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Jupiter Neurosciences Total Payout Yield % Related Terms

Jupiter Neurosciences Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences Total Payout Yield % Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 -2.79 0.00

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

JUNS vs ZEOX, LEXX, GDTC: Total Payout Yield % Comparison

For the Biotechnology subindustry, Jupiter Neurosciences's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jupiter Neurosciences Total Payout Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Jupiter Neurosciences's Total Payout Yield % falls into.


JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Jupiter Neurosciences's Total Payout Yield % for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 0 + 0) / 35.13492
=0.00%

Jupiter Neurosciences's annualized Total Payout Yield % for the quarter that ended in Mar. 2026 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 13.6489122
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of 0.00 mean?
Jupiter Neurosciences (JUNS) has a Total Payout Yield % of 0.00 as of Jul. 17, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Jupiter Neurosciences and its competitors.
Is Jupiter Neurosciences' Total Payout Yield % too high?
Jupiter Neurosciences' current Total Payout Yield % is 0.00. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' Total Payout Yield % compare to ZEOX and LEXX?
Jupiter Neurosciences' Total Payout Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Biotechnology company?
A good Total Payout Yield % depends on the Biotechnology industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current Total Payout Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Total Payout Yield % of 0.00. The current Total Payout Yield % is 0.00. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Total Payout Yield % is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price